Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer
Authors:
Open Access
- 1 December 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (12) , 1971-1972
Abstract
Human epidermal growth factor receptor 2 (ERBB2)-targeted therapies such as trastuzumab improve disease-free and overall survival for patients with ERBB2-positive breast cancer (BCA).1 Cardiotoxic effects, characterized by reduced left ventricular ejection fraction (LVEF) or clinical heart failure (HF), are an important treatment-limiting adverse effect of ERBB2-targeted therapy and the most common indication for early trastuzumab interruption.2 Findings from the PHARE and PERSEPHONE trials on the noninferiority of 6- vs 12-month durations of trastuzumab are conflicting, thus the clinical significance of early trastuzumab interruption on BCA outcomes remains uncertain.3,4 Our primary objective was to evaluate the association of early trastuzumab interruption with BCA outcomes in clinical practice.Keywords
This publication has 6 references indexed in Scilit:
- Safety of Continuing Trastuzumab Despite Mild CardiotoxicityJACC: Cardiooncology, 2019
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialThe Lancet, 2019
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialThe Lancet, 2019
- Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyBreast Cancer Research and Treatment, 2019
- Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancerBreast Cancer Research and Treatment, 2015
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011